Mooren's Ulcer

Comprehensive Clinical Guide: Mooren’s Ulcer (Chronic Peripheral Ulcerative Keratitis)

1. Introduction and Clinical Overview

Mooren’s ulcer is a rare, painful, chronic, and progressive peripheral ulcerative keratitis (PUK) characterized by an inflammatory excavation of the corneal stroma. Unlike peripheral corneal thinning associated with systemic autoimmune diseases (such as rheumatoid arthritis or Wegener’s granulomatosis), Mooren’s ulcer is considered an isolated, idiopathic autoimmune process directed specifically against corneal antigens.

The condition is notoriously difficult to manage, often characterized by severe pain, photophobia, and a relentless progression that can lead to corneal perforation and subsequent blindness. It predominantly affects the peripheral cornea, initiating as an infiltrate that eventually ulcerates and spreads circumferentially and centrally.

2. Etiology and Pathophysiology

The precise trigger for Mooren’s ulcer remains elusive, though it is widely accepted as an autoimmune phenomenon. The disease is thought to be mediated by both humoral and cell-mediated immune responses against corneal-specific antigens.

Key Mechanisms:

• Antigenic Trigger: It is hypothesized that previous trauma, surgery (e.g., cataract extraction), or infection may expose sequestered corneal antigens, triggering a localized immune reaction.
• Auto-antibody Production: Research has identified the presence of circulating antibodies against corneal epithelium and stroma in affected patients.
• Matrix Metalloproteinases (MMPs): The clinical destruction of the corneal stroma is driven by the upregulation of collagenases and gelatinases (MMP-2 and MMP-9), which degrade the collagen scaffold of the cornea.
• T-Cell Infiltration: Histopathological analysis reveals a heavy infiltration of lymphocytes, plasma cells, and neutrophils at the ulcer base, indicative of a Type IV hypersensitivity reaction.

3. Clinical Presentation and Staging

Mooren’s ulcer typically presents in two distinct forms: the Benign (Unilateral) form and the Malignant (Bilateral) form.

Clinical Features:

• Symptoms: Intense, often intractable ocular pain, severe photophobia, excessive lacrimation, and blurred vision.
• Signs:
  • Peripheral crescentic ulceration.
  • Overhanging edges of the ulcer (the central edge is undermined).
  • Vascularization of the ulcer bed.
  • Conjunctival injection and chemosis adjacent to the lesion.

The Three Stages of Progression:

4. Diagnostic Workup and Differential Diagnosis

Diagnosis is primarily clinical, but it is a "diagnosis of exclusion." Practitioners must rule out systemic autoimmune conditions that cause peripheral corneal thinning.

Key Diagnostic Tests:

1. Slit-Lamp Biomicroscopy: Essential for identifying the characteristic "overhanging edge" of the ulcer.
2. Systemic Workup: CBC, ESR, CRP, Rheumatoid Factor (RF), ANA, ANCA, and chest X-ray to exclude systemic vasculitis.
3. Corneal Scraping/Biopsy: Performed only if infectious keratitis (bacterial, fungal, or acanthamoeba) is suspected.
4. Immunohistochemistry: Analysis of biopsy tissue for immunoglobulin and complement deposition.

Differential Diagnosis Table:

5. Management Strategies

Management is notoriously challenging and requires a multidisciplinary approach involving ophthalmology, rheumatology, and ocular immunology.

Medical Therapy:

• Topical Corticosteroids: The mainstay of initial therapy, though often insufficient for severe cases.
• Systemic Immunosuppression: Methotrexate, Cyclosporine, or Mycophenolate mofetil are frequently required to control the autoimmune response.
• Biological Agents: TNF-alpha inhibitors (e.g., Infliximab) have shown promise in refractory cases.

Surgical Intervention:

Surgical management is indicated when medical therapy fails or when perforation is imminent.
* Conjunctival Resection: Removal of the inflamed conjunctiva adjacent to the ulcer (debulking) to remove the source of inflammatory cytokines/MMPs.
* Lamellar Keratoplasty: Used to patch the thinned stroma.
* Glue and Patch: Cyanoacrylate glue and bandage contact lenses for micro-perforations.

6. Risks, Contraindications, and Prognostic Outlook

The prognosis for Mooren’s ulcer is generally guarded. The malignant bilateral form is particularly aggressive and carries a high risk of visual loss.

• Contraindications: Avoidance of aggressive surgical procedures (like penetrating keratoplasty) during the active inflammatory phase is critical, as the host immune system will likely reject the graft.
• Risks: High risk of secondary glaucoma, cataract formation (due to long-term steroid use), and permanent corneal scarring.
• Prognosis: Early diagnosis and aggressive systemic immunosuppression are the only factors that improve visual outcomes. Patients require lifelong monitoring.

7. Frequently Asked Questions (FAQ)

1. Is Mooren’s ulcer contagious?
No. It is an autoimmune condition, not an infectious disease. It cannot be transmitted from person to person.

2. Why is the pain so severe in Mooren’s ulcer?
The peripheral cornea is densely innervated by the trigeminal nerve. The inflammatory process exposes these nerve endings, causing chronic, stabbing, and debilitating pain.

3. Does Mooren’s ulcer always affect both eyes?
Not necessarily. The "benign" form is typically unilateral and seen in older patients, whereas the "malignant" form is usually bilateral, more aggressive, and seen in younger patients.

4. Can I wear contact lenses with Mooren’s ulcer?
Generally, no. Contact lenses can exacerbate the ulceration and increase the risk of secondary infection. They should only be used under strict supervision as "bandage" lenses.

5. Is there a genetic component to Mooren’s ulcer?
While not strictly hereditary, there is evidence of an association with specific HLA (Human Leukocyte Antigen) types, suggesting a genetic predisposition to the autoimmune response.

6. What is the role of conjunctival resection?
The conjunctiva adjacent to the ulcer is the source of the inflammatory cells and MMPs. Removing this tissue (the "conjunctival flap") helps halt the chemical signaling that promotes corneal melting.

7. How long does the treatment last?
Treatment is often required for months or even years. Because it is an autoimmune condition, tapering immunosuppressants too quickly often results in a rebound of the ulceration.

8. Can Mooren’s ulcer cause blindness?
Yes. Without treatment, the ulcer can progress to central corneal perforation, endophthalmitis, or phthisis bulbi (shrunken eye), leading to total vision loss.

9. Are there any dietary changes that help?
There is no specific diet for Mooren’s ulcer, but maintaining a healthy inflammatory profile through a balanced diet (high in Omega-3 fatty acids) is generally advised for all autoimmune conditions.

10. Why is this called "Mooren's" ulcer?
It is named after the German ophthalmologist Albert Mooren, who first described the clinical characteristics of the condition in the 19th century.

8. Conclusion

Mooren’s ulcer remains one of the most challenging diagnoses in clinical ophthalmology. Its relentless, erosive nature requires a high index of suspicion from the primary eye care provider. By understanding the pathophysiology—specifically the role of MMPs and the autoimmune nature of the disease—clinicians can move beyond symptomatic treatment and implement effective, systemic immunosuppressive strategies. Early intervention remains the gold standard for preserving ocular integrity and visual function. Patients must be counseled on the chronic nature of the condition and the necessity of long-term adherence to therapeutic protocols to prevent catastrophic outcomes.